- Phase I study evaluating safety and tolerability of VXM01 in pancreatic cancer - VAXIMM AG, a Swiss-German biotech company focusing on oral cancer vaccines, announced today follow-on data from the first clinical trial of its investigational oral T-cell vaccine VXM01. Data of a trial extension of the
BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a new approx. 10,000 square-meters (108,000 square-feet) headquarters and research facility.
Nijmegen, Netherlands and Neuried, Germany; May 6, 2014: Synthon Biopharmaceuticals BV and MAB Discovery GmbH today announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibodydrug conjugates (ADCs) and alternative antibody-based therapeutics.
MAB Discovery GmbH, a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel antibody therapeutics, today announced it has entered into a collaboration with Genmab A/S (OMX: GEN) and its affiliate Genmab BV.
Munich, Germany, February 26th, 2014: SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases, today announced the first publication covering the key characteristics and therapeutic potential of its monoclonal anti-FcRIIB-antibody SM201.
CatCap, together with Tenzing partners, proudly present the Venture Lounge Biotech to be held in Luxembourg with the support of the Ministry of the Economy. The Venture Lounge will take place on Wednesday, April 30, for investors and selected entrepreneurs.